Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Rivegauge	1/19/2019 9:21:15 AM
	Read Replies (1) of 63332

They received a 483, the meet with FDA after the official 483 is issued . They had been having meetings with the FDA since including face to face . Typhcallh you get approval letter / rejection or conditional approval. I am not sure why it appears most people want to blame the FDA when it’s apparent they had not done west been told One should ask , - who is in charge of Mfg? - since they had over a year to work on things ( this is a fact not a wild accusation) they became aware of this in 2017 by employees prior to Morris taking over everything - who read the FDA meeting minutes? - what was the plan they proposed to FDA and timeline associated? Hopefully in couple of months the dust will settle and more I formation ( accurate on hopes not from Immu ) will surface to put this to rest . This is based on facts and biotech/ fda experience

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next